Tirzepatide
COMMIT-UC
Eli Lilly · Phase 3 · Recruiting · Enrollment 350
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Mirikizumab + Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| Mirikizumab + Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.